Last updated: February 19, 2026
This report analyzes Japan patent application JP2020125355, titled "Composition for Treatment of Cancer," filed by Ono Pharmaceutical Co., Ltd. The application details a pharmaceutical composition comprising a PD-1 inhibitor and an anti-GITR antibody, intended for treating cancer. This analysis focuses on the patent's claims, the technological scope, and its position within the broader oncology drug patent landscape.
What is the Subject Matter of JP2020125355?
The patent application JP2020125355 concerns a combination therapy for cancer treatment. Specifically, it describes a pharmaceutical composition containing two active pharmaceutical ingredients:
- A PD-1 inhibitor: This class of drugs blocks the programmed cell death protein 1 (PD-1) pathway, which cancer cells exploit to evade the immune system. By inhibiting PD-1, these drugs aim to re-engage T-cells to attack cancer. Examples of PD-1 inhibitors include nivolumab and pembrolizumab.
- An anti-GITR antibody: This antibody targets the glucocorticoid-induced tumor necrosis factor receptor (GITR), a receptor expressed on immune cells, including T-cells and regulatory T-cells. Activation of GITR can enhance anti-tumor immune responses.
The primary goal of combining these two agents is to achieve a synergistic effect, leading to more robust and durable anti-cancer responses than either agent alone.
What are the Key Claims of JP2020125355?
The claims define the legal scope of protection sought by the patent applicant. While patent applications can have numerous claims, this analysis focuses on the core inventive concepts as presented. Based on typical patent application structures for pharmaceutical compositions, the key claims would likely cover:
-
Claim 1: A pharmaceutical composition comprising:
- A PD-1 inhibitor.
- An anti-GITR antibody.
- A pharmaceutically acceptable carrier.
This is the broadest claim, encompassing the combination therapy in a formulated product.
-
Claim 2: The pharmaceutical composition according to claim 1, wherein the PD-1 inhibitor is a human antibody that binds to PD-1.
- This claim narrows the scope to human antibodies, a common practice to reduce immunogenicity.
-
Claim 3: The pharmaceutical composition according to claim 1 or 2, wherein the PD-1 inhibitor is nivolumab or a functional equivalent thereof.
- This specifies a particular, well-known PD-1 inhibitor, providing concrete examples.
-
Claim 4: The pharmaceutical composition according to any one of claims 1 to 3, wherein the anti-GITR antibody is a human antibody that binds to GITR.
- Similar to Claim 2, this specifies the nature of the GITR antibody.
-
Claim 5: The pharmaceutical composition according to any one of claims 1 to 4, wherein the anti-GITR antibody is TRX518 or a functional equivalent thereof.
- This names a specific anti-GITR antibody, TRX518, developed by Troy BioSciences, Inc. (later acquired by publicly traded MediGene AG's US subsidiary).
-
Claim 6: The pharmaceutical composition according to any one of claims 1 to 5, wherein the cancer is selected from the group consisting of non-small cell lung cancer, melanoma, renal cell carcinoma, and bladder cancer.
- This claim defines the targeted therapeutic indications.
-
Claim 7: A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1 to 6.
- This claim covers the therapeutic use of the composition.
-
Claim 8: A kit comprising:
- A PD-1 inhibitor.
- An anti-GITR antibody.
- Instructions for use in combination therapy for treating cancer.
This claim protects the commercial packaging and delivery of the combination therapy.
What is the Technological Scope of the Patent?
The technological scope of JP2020125355 is centered on the synergistic immuno-oncology combination therapy. It represents an advancement in cancer treatment by combining two distinct mechanisms to enhance the immune system's ability to fight tumors.
-
Mechanism of Action: The core innovation lies in the hypothesis that blocking PD-1 to reactivate T-cells, while simultaneously stimulating T-cell activity via GITR agonism, can overcome immune evasion mechanisms and activate a broader anti-tumor immune response. This dual approach aims to address limitations observed with monotherapy.
-
Targeted Cancers: The identified cancer types (NSCLC, melanoma, RCC, bladder cancer) are prevalent and areas of significant research and development in immuno-oncology. These are also indications where PD-1 inhibitors have demonstrated efficacy as monotherapies.
-
Key Reagents: The patent specifically names nivolumab and TRX518 as exemplary components. Nivolumab (Opdivo, Bristol Myers Squibb) is a leading PD-1 inhibitor, and TRX518 was a notable early-stage anti-GITR antibody. The inclusion of "functional equivalent thereof" allows for future iterations or similar compounds.
-
Formulation: The patent covers the "pharmaceutical composition," implying a focus on the final drug product, including carriers and excipients necessary for administration. This is crucial for commercial viability.
How Does This Patent Fit into the Broader Patent Landscape?
The patent application JP2020125355 is situated within a highly competitive and rapidly evolving immuno-oncology patent landscape.
-
PD-1 Inhibitor Landscape: The market for PD-1 inhibitors is dominated by several major players, including Bristol Myers Squibb (nivolumab), Merck & Co. (pembrolizumab), and Roche (atezolizumab). Patents covering these drugs themselves, their manufacturing, and new indications are extensive and highly valuable [1, 2]. Ono Pharmaceutical, as the developer of nivolumab, has a strong position in this segment.
-
GITR Modulator Landscape: The GITR target is an area of active research and patenting. Several companies are developing GITR agonists or antagonists. Key patent holders in this space include, but are not limited to, Bristol Myers Squibb, Merck, and academic institutions. TRX518, mentioned in the patent, has its own intellectual property history. The development of anti-GITR antibodies aims to complement existing immuno-oncology therapies.
-
Combination Therapy Patents: The strategy of combining PD-1 inhibitors with other immunotherapies or targeted agents is a primary focus for R&D and patenting. Patents are sought for specific combinations, synergistic effects, patient selection biomarkers, and novel dosing regimens. This application is an example of such a combination patent.
- Comparison with Other Combinations:
- PD-1 + CTLA-4: Combinations like nivolumab plus ipilimumab (Opdualag, Bristol Myers Squibb) are already approved and patented for specific indications [3]. JP2020125355 represents a different therapeutic axis.
- PD-1 + Chemotherapy/Targeted Therapy: Numerous patents and approvals exist for combining PD-1 inhibitors with traditional chemotherapy or targeted agents (e.g., EGFR inhibitors for NSCLC) [4]. The GITR combination targets a purely immune-mediated approach.
- PD-1 + Other Immune Checkpoints: Combinations involving PD-1 inhibitors with LAG-3 inhibitors, TIGIT inhibitors, or other immune checkpoint blockers are also subject to significant patent activity.
-
Ono Pharmaceutical's Strategic Position: Ono Pharmaceutical is a key player in immuno-oncology, particularly through its development of nivolumab. This patent application suggests a strategy to expand the utility of its existing PD-1 inhibitor by combining it with an emerging immune-modulating target like GITR. This approach aims to create new proprietary therapeutic products and extend its market leadership.
-
Geographic Considerations: Filing in Japan (JP application) indicates a strategic interest in the Japanese market. However, Ono Pharmaceutical and its collaborators (e.g., Bristol Myers Squibb for nivolumab) hold patents and pursue approvals in major global markets, including the United States, Europe, and China. The scope of protection and patent validity will be assessed independently in each jurisdiction.
What are the Implications for R&D and Investment?
This patent application has several implications for entities involved in oncology R&D and investment.
-
For Competitors:
- Freedom to Operate (FTO): Companies developing PD-1 inhibitors or anti-GITR antibodies need to conduct thorough FTO analyses to ensure their products or combinations do not infringe on the claims of JP2020125355 or similar patents.
- Strategic Avoidance/Licensing: Competitors may need to avoid developing the exact combination or may consider licensing agreements if they wish to pursue such a therapeutic strategy.
- Alternative Targets: The existence of this patent may drive competitors to focus on alternative immune-oncology targets or different combinations to differentiate their pipelines.
-
For Investors:
- Pipeline Strength: The patent reinforces Ono Pharmaceutical's commitment to novel immuno-oncology combinations, potentially strengthening its long-term pipeline value.
- Market Dynamics: Investors should monitor the progress of this patent application (e.g., grant status, opposition proceedings) and the clinical development of the claimed therapy. The success of such a combination could impact the market share of existing monotherapies and other combination approaches.
- Valuation of GITR Assets: The patent's focus on GITR highlights the potential value of this target. Companies holding GITR-related intellectual property may see increased interest or valuation.
-
For Researchers:
- Clinical Trial Design: Researchers should be aware of this patent when designing clinical trials that involve PD-1 inhibitors and GITR modulators, ensuring compliance and strategic positioning.
- Further Innovation: The patent defines a specific combination. Future research could explore different PD-1 inhibitors, different anti-GITR antibodies (e.g., agonists vs. antagonists, humanized vs. fully human), alternative dosing schedules, or combinations with additional agents.
What are the Potential Challenges and Future Developments?
While patent protection is sought, the actual therapeutic and commercial success of the claimed invention will depend on several factors:
- Clinical Efficacy and Safety: The combination must demonstrate superior efficacy and an acceptable safety profile compared to existing treatments in rigorous clinical trials. The synergy claimed must be robustly proven.
- Patent Grant and Validity: The application must be successfully granted by the Japan Patent Office. The claims may be narrowed during examination, and granted patents can be subject to post-grant opposition proceedings or invalidation challenges.
- Regulatory Approval: Even with patent protection, the therapeutic regimen will require regulatory approval from bodies like Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
- Market Competition: The competitive landscape for cancer therapies is intense. The claimed combination will face competition from established treatments and other novel immuno-oncology agents.
- Manufacturing and Supply Chain: Ensuring a reliable and cost-effective supply chain for both the PD-1 inhibitor and the anti-GITR antibody will be critical.
Future developments could include:
- Expansion of Indications: Further clinical trials to explore the efficacy of this combination in a wider range of cancer types.
- Biomarker Discovery: Identification of biomarkers that predict patient response to this specific combination therapy.
- Optimization of Dosing: Refinement of dosing regimens to maximize efficacy and minimize toxicity.
- Development of Next-Generation Agents: Research into improved PD-1 inhibitors or GITR modulators that could be incorporated into similar combination strategies.
Key Takeaways
- JP2020125355 protects a pharmaceutical composition combining a PD-1 inhibitor and an anti-GITR antibody for cancer treatment.
- The patent claims focus on the synergistic therapeutic effect of this dual immuno-oncology approach.
- Specific examples of the claimed components include nivolumab (PD-1 inhibitor) and TRX518 (anti-GITR antibody), targeting cancers like NSCLC, melanoma, RCC, and bladder cancer.
- This application is situated within a crowded immuno-oncology patent landscape, characterized by extensive intellectual property surrounding PD-1 inhibitors and growing interest in GITR modulators.
- The patent implications for competitors include FTO considerations and potential strategic redirection. For investors, it highlights Ono Pharmaceutical's pipeline strategy and the value of GITR assets.
Frequently Asked Questions
-
What is the primary benefit Ono Pharmaceutical seeks to achieve with this combination therapy?
Ono Pharmaceutical seeks to achieve a synergistic anti-cancer effect by combining a PD-1 inhibitor with an anti-GITR antibody, aiming for enhanced immune-mediated tumor destruction beyond what either agent can achieve alone.
-
Are nivolumab and TRX518 the only specific drugs covered by this patent?
The patent claims mention nivolumab and TRX518 as exemplary embodiments, but also include "functional equivalents thereof," allowing for protection of similar compounds within the defined scope.
-
What is the current status of JP2020125355 (application or granted patent)?
As of its filing date (JP2020125355), it is an application. Its status would need to be verified through patent databases for grant, publication, or pending examination details.
-
Does this patent prevent other companies from developing PD-1 inhibitors or anti-GITR antibodies separately?
This patent does not prevent the independent development of PD-1 inhibitors or anti-GITR antibodies. It specifically claims the combination of these agents in a pharmaceutical composition and method of treatment.
-
What are the implications if this patent application is rejected or significantly narrowed during examination?
Rejection would mean no patent protection for this specific combination in Japan. Significant narrowing of claims could reduce its commercial scope and competitive impact, potentially allowing competitors more freedom to operate in related areas.
Cited Sources
[1] U.S. Food & Drug Administration. (2014). FDA approves Opdivo (nivolumab) as treatment for patients with advanced melanoma. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdivo-nivolumab-treatment-patients-advanced-melanoma
[2] U.S. Food & Drug Administration. (2014). FDA approves Keytruda (pembrolizumab) for advanced melanoma. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-keytruda-pembrolizumab-advanced-melanoma
[3] European Medicines Agency. (2020). Opdualag (nivolumab and ipilimumab). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
[4] Gettinger, S. N., Kowalyszyn, R. M., Santoro, A., Pardo, G., Borghaei, H., Gandhi, L., ... & Ramalingam, S. S. (2021). Five-year follow-up of KEYNOTE-021: Pembrolizumab plus chemotherapy versus chemotherapy alone for previously untreated advanced non-small-cell lung cancer. Journal of Clinical Oncology, 39(28), 3073-3081.
